论文部分内容阅读
目的系统评价凡德他尼联合多烯紫杉醇治疗晚期非小细胞肺癌的疗效和安全性。方法计算机检索EMbase、Cochrane Library、PubMed、万方、VIP、CNKI、CBM等数据库,检索时间从建库至2010年10月26日,查找有关凡德他尼联合多烯紫杉醇与单用多烯紫杉醇比较治疗晚期非小细胞肺癌的随机对照试验(RCT),按纳入排除标准选择文献、提取资料和评价质量后,采用RevMan5.0软件进行Meta分析。结果共纳入3个RCT,共1626例患者。Meta分析结果显示:与对照组相比,凡德他尼能提高患者客观缓解率[OR=1.81,95%CI(1.37,2.38),P<0.0001],在疾病控制率、1年生存率方面也有积极意义,且所有纳入研究均显示,凡德他尼能明显延长患者无进展生存期(PFS)。结论与单用多烯紫杉醇相比,凡德他尼联合多烯紫杉醇治疗晚期非小细胞肺癌疗效更好,且无明显毒副作用,在临床上具有一定的应用价值。
Objective To evaluate the efficacy and safety of vandetanib plus docetaxel in the treatment of advanced non-small cell lung cancer. Methods The databases of EMbase, Cochrane Library, PubMed, Wanfang, VIP, CNKI and CBM were searched by computer. The search time was from database construction to October 26, 2010. The data were searched for vandetanib combined with docetaxel and docetaxel Randomized controlled trials (RCTs) were compared for the treatment of advanced non-small cell lung cancer (NSCLC). According to inclusion criteria, literature selection, data extraction and quality evaluation, Meta-analysis was performed using RevMan 5.0 software. Results A total of 3 RCTs were enrolled, with a total of 1626 patients. Meta-analysis showed that vandetanib increased the objective response rate (OR = 1.81, 95% CI, 1.37, 2.38, P <0.0001) in patients with control over disease control and 1-year survival Also had positive implications, and all included studies showed that vandetanib significantly prolonged patient progression-free survival (PFS). Conclusions Vandetanib combined with docetaxel is more effective than docetaxel alone in the treatment of advanced non-small cell lung cancer, and has no obvious side effects. It is clinically valuable.